US6008237A
(en)
|
1997-12-19 |
1999-12-28 |
Merck & Co., Inc. |
Arylthiazolidinedione derivatives
|
WO2000066572A1
(en)
|
1999-04-28 |
2000-11-09 |
Dr. Reddy's Research Foundation |
Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
|
BR0010126A
(en)
*
|
1999-04-28 |
2002-02-26 |
Aventis Pharma Gmbh |
Tri-aryl acid derivatives as ppar receptor ligands
|
BR0010605A
(en)
*
|
1999-04-28 |
2002-02-13 |
Aventis Pharma Gmbh |
Acid derivatives of di-aryl as ligands for ppar receptors
|
AU770870B2
(en)
|
1999-06-18 |
2004-03-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
DE60029446T2
(en)
|
1999-06-18 |
2007-02-08 |
Merck & Co., Inc. |
ARYLTHIAZOLIDEINDIONE AND ARYLOXAZOIDIDE DERIVATIVES
|
GB9914977D0
(en)
|
1999-06-25 |
1999-08-25 |
Glaxo Group Ltd |
Chemical compounds
|
GB9917405D0
(en)
*
|
1999-07-23 |
1999-09-22 |
Univ Dundee |
Methods of treatment and drug screening methods
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
TW200514783A
(en)
|
1999-09-22 |
2005-05-01 |
Bristol Myers Squibb Co |
Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
|
EP1284728A4
(en)
*
|
1999-10-22 |
2004-05-19 |
Merck & Co Inc |
Pharmaceuticals for treating obesity
|
WO2001066098A2
(en)
*
|
2000-03-09 |
2001-09-13 |
Aventis Pharma Deutschland Gmbh |
Therapeutic uses of ppar mediators
|
JP4988128B2
(en)
|
2000-07-13 |
2012-08-01 |
イーライ リリー アンド カンパニー |
β3 adrenergic agonist
|
WO2002007765A2
(en)
*
|
2000-07-20 |
2002-01-31 |
Bristol-Myers Squibb Company |
REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE
|
GB0024361D0
(en)
*
|
2000-10-05 |
2000-11-22 |
Glaxo Group Ltd |
Medicaments
|
GB0024362D0
(en)
*
|
2000-10-05 |
2000-11-22 |
Glaxo Group Ltd |
Medicaments
|
JP4236464B2
(en)
|
2000-10-26 |
2009-03-11 |
フォーリナー ラボラトリーズ アイルランド リミテッド |
Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction
|
WO2002046154A1
(en)
*
|
2000-12-05 |
2002-06-13 |
Nippon Chemiphar Co., Ltd. |
Peroxisome proliferator activated receptor d activators
|
EP1911462A3
(en)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Compositions comprising a sterol absorption inhibitor
|
AU2002243778A1
(en)
*
|
2001-02-02 |
2002-09-19 |
Smithkline Beecham Corporation |
Treatment of ppar mediated diseases
|
AU2002336267B2
(en)
*
|
2001-03-08 |
2006-10-05 |
Merck & Co., Inc. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
DE60205891T2
(en)
|
2001-03-12 |
2006-06-22 |
Intercept Pharmaceuticals, Inc. |
STEROIDS AS AGONISTS FOR FXR
|
EA006556B1
(en)
|
2001-03-27 |
2006-02-24 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6916814B2
(en)
|
2001-07-11 |
2005-07-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
CA2452246A1
(en)
|
2001-07-17 |
2003-01-30 |
Teijin Limited |
Method of screening substance by measuring ppar .delta. activating effect and agent
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
PL208515B1
(en)
|
2001-08-31 |
2011-05-31 |
Sanofi Aventis Deutschland |
Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
AU2002336532C1
(en)
|
2001-09-14 |
2008-10-16 |
Amgen, Inc |
Linked biaryl compounds
|
US6833380B2
(en)
|
2002-03-07 |
2004-12-21 |
Warner-Lambert Company, Llc |
Compounds that modulate PPAR activity and methods of preparation
|
US6867224B2
(en)
|
2002-03-07 |
2005-03-15 |
Warner-Lambert Company |
Compounds that modulate PPAR activity and methods of preparation
|
US6875780B2
(en)
|
2002-04-05 |
2005-04-05 |
Warner-Lambert Company |
Compounds that modulate PPAR activity and methods for their preparation
|
WO2004004665A2
(en)
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
EP1388352A1
(en)
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
MXPA05002411A
(en)
|
2002-09-05 |
2005-05-27 |
Novo Nordisk As |
Novel vinyl carboxylic acid derivatives and their therapeutical use.
|
FR2845602B1
(en)
*
|
2002-10-11 |
2005-07-08 |
Servier Lab |
ASSOCIATION BETWEEN A LIGAND OF RECEPTORS ACTIVE BY PEROXISOME PROLIFIERS AND AN ANTIOXIDANT AGENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
US20050080115A1
(en)
|
2002-10-28 |
2005-04-14 |
Lone Jeppesen |
Novel compounds, their preparation and use
|
DE60332860D1
(en)
|
2002-10-28 |
2010-07-15 |
High Point Pharmaceuticals Llc |
NEW COMPOUNDS SUITABLE FOR THE TREATMENT OF PPARIALLY DISTRIBUTED DISEASES
|
RU2349582C2
(en)
|
2002-10-28 |
2009-03-20 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
New compounds and their use as ppar-modulators
|
US7129268B2
(en)
|
2002-10-28 |
2006-10-31 |
Novo Nordisk A/S |
Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
|
US6653334B1
(en)
|
2002-12-27 |
2003-11-25 |
Kowa Co., Ltd. |
Benzoxazole compound and pharmaceutical composition containing the same
|
DE10308351A1
(en)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments
|
WO2004092130A2
(en)
*
|
2003-04-07 |
2004-10-28 |
Kalypsys, Inc. |
N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
|
US7244763B2
(en)
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
JPWO2004093910A1
(en)
*
|
2003-04-22 |
2006-07-13 |
アステラス製薬株式会社 |
A therapeutic agent for cranial neurodegenerative diseases with PPARδ agonist
|
NZ545692A
(en)
|
2003-09-03 |
2009-02-28 |
Kowa Co |
PPAR-activating compound and pharmaceutical composition containing same
|
US20070135485A1
(en)
|
2003-10-22 |
2007-06-14 |
Gillig James R |
Novel mch receptor antagonists
|
US20080207685A1
(en)
*
|
2003-11-20 |
2008-08-28 |
Eli Lilly And Company |
Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
|
GB0403148D0
(en)
*
|
2004-02-12 |
2004-03-17 |
Smithkline Beecham Corp |
Chemical compounds
|
DK1734970T3
(en)
|
2004-03-12 |
2015-02-16 |
Intercept Pharmaceuticals Inc |
Treatment of fibrosis using FXR ligands
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
EP1730520A2
(en)
*
|
2004-03-24 |
2006-12-13 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
|
RU2006138495A
(en)
*
|
2004-04-01 |
2008-05-10 |
Авентис Фармасьютикалз Инк. (Us) |
USE OF RECEPTOR AGONISTS ACTIVATED BY DELTA PEROXISOMIS PROLIFERATOR FOR TREATMENT OF PC AND OTHER DEMIELINIZING DISEASES
|
WO2005097127A2
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Method of treating men with metabolic and anthropometric disorders
|
ATE486055T1
(en)
|
2004-05-05 |
2010-11-15 |
High Point Pharmaceuticals Llc |
NEW COMPOUNDS, THEIR PRODUCTION AND USE
|
US8053598B2
(en)
|
2004-05-05 |
2011-11-08 |
High Point Pharmaceuticals, Llc |
Compounds, their preparation and use
|
KR20070036076A
(en)
|
2004-05-25 |
2007-04-02 |
메타볼렉스, 인코포레이티드 |
Substituted triazoles as modulators of ppar and methods of their preparation
|
DOP2005000123A
(en)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
CETP INHIBITORS
|
CA2581072A1
(en)
|
2004-09-16 |
2006-03-30 |
Merck & Co., Inc. |
Compounds for the treatment of dyslipidemia and other lipid disorders
|
AU2006204334B2
(en)
|
2005-01-10 |
2012-02-23 |
Cortendo Ab (Publ) |
Methods and compositions for treating diabetes, metabolic syndrome and other conditions
|
EP1865778A4
(en)
|
2005-03-21 |
2010-12-08 |
Metabolex Inc |
Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders
|
TW200724138A
(en)
|
2005-03-29 |
2007-07-01 |
Sk Corp |
Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
|
ITMI20050912A1
(en)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
|
ATE529404T1
(en)
|
2005-06-30 |
2011-11-15 |
High Point Pharmaceuticals Llc |
PHENOXYACETIC ACIDS AS PPAR-DELTA ACTIVATORS
|
FR2890071B1
(en)
|
2005-08-30 |
2007-11-09 |
Fournier Sa Sa Lab |
NEW INDOLE COMPOUNDS
|
FR2890072A1
(en)
|
2005-09-01 |
2007-03-02 |
Fournier S A Sa Lab |
New pyrrolopyridine derivatives are peroxisome proliferator activated receptor activators useful to treat e.g. hypertriglyceridimia, hyperlipidemia, hypercholesterolemia and diabetes
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
EA015717B1
(en)
|
2005-12-22 |
2011-10-31 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Phenoxy acetic acids as ppar delta activators
|
CA2637803A1
(en)
|
2006-01-18 |
2007-12-06 |
Evolva Sa |
Ppar modulators
|
US7943612B2
(en)
|
2006-03-09 |
2011-05-17 |
High Point Pharmaceuticals, Llc |
Compounds that modulate PPAR activity, their preparation and use
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
NZ576569A
(en)
|
2006-10-02 |
2012-05-25 |
Cortendo Ab Publ |
Ketoconazole enantiomer in humans
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
US20080187928A1
(en)
|
2006-12-29 |
2008-08-07 |
The Salk Institute For Biological Studies |
Methods for enhancing exercise performance
|
BRPI0806686A2
(en)
|
2007-01-18 |
2014-11-04 |
Evolva Sa |
COMPOUNDS AND ITS USES, METHODS OF TREATMENT OR PREVENTION, PHARMACEUTICAL COMPOSITIONS AND CRYSTALLINE COMPOUND AND SOLVAT
|
ES2609825T3
(en)
|
2007-01-18 |
2017-04-24 |
Evolva Sa |
1,3-substituted dioxanes useful as PPAR modulators
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
US8168815B2
(en)
|
2007-01-26 |
2012-05-01 |
Kaneq Pharma Inc. |
Fused aromatic PTP-1B inhibitors
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
WO2008118948A1
(en)
|
2007-03-26 |
2008-10-02 |
Atherogenics, Inc. |
Methods and compositions of derivatives of probucol for the treatment of diabetes
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
US8338458B2
(en)
|
2007-05-07 |
2012-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
CA2689525A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
RU2527177C2
(en)
|
2007-12-20 |
2014-08-27 |
Энвиво Фармасьютикалз, Инк. |
Tetrasubstituted benzenes
|
CN101531638B
(en)
|
2008-03-13 |
2011-12-28 |
中国科学院广州生物医药与健康研究院 |
Compound used as a regulator of estrogen-related receptor and applications thereof
|
US8343990B2
(en)
|
2008-04-14 |
2013-01-01 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
CN101628913B
(en)
|
2008-07-18 |
2013-01-23 |
中国科学院广州生物医药与健康研究院 |
Compound as estrogen-related receptor modulator and application thereof
|
CA2732323C
(en)
|
2008-07-30 |
2017-06-27 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
ES2712052T3
(en)
|
2008-10-17 |
2019-05-09 |
Cymabay Therapeutics Inc |
Methods to reduce small and dense LDL particles
|
AU2009307884B2
(en)
|
2008-10-22 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EA201170624A1
(en)
|
2008-10-30 |
2011-12-30 |
Мерк Шарп Энд Домэ Корп. |
ISONICOTINAMIDE ANTAGONISTS OF OREXIN RECEPTORS
|
CN102271509A
(en)
|
2008-10-31 |
2011-12-07 |
默沙东公司 |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EP2358200A4
(en)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
Substituted bicyclic amines for the treatment of diabetes
|
MX2011005295A
(en)
|
2008-11-19 |
2011-06-24 |
Intercept Pharmaceuticals Inc |
Tgr5 modulators and method of use thereof.
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
CA2749891A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Bridged and fused antidiabetic compounds
|
US8575166B2
(en)
|
2009-02-05 |
2013-11-05 |
Merck Sharp & Dohme Corp. |
Phthalazine-containing antidiabetic compounds
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
AU2010317842A1
(en)
|
2009-11-16 |
2012-07-12 |
Mellitech |
[1,5]-diazocin derivatives
|
EP3255038A1
(en)
|
2009-12-18 |
2017-12-13 |
Ogeda Sa |
Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43)
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
WO2011088025A1
(en)
|
2010-01-15 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
US8785634B2
(en)
|
2010-04-26 |
2014-07-22 |
Merck Sharp & Dohme Corp |
Spiropiperidine prolylcarboxypeptidase inhibitors
|
WO2011137054A1
(en)
|
2010-04-30 |
2011-11-03 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
WO2011151434A1
(en)
|
2010-06-04 |
2011-12-08 |
Euroscreen S.A. |
Novel compounds, pharmaceutical composition and methods for use in treating metabolic disorders
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
AU2011296737A1
(en)
|
2010-08-31 |
2013-04-11 |
Snu R&Db Foundation |
Use of the fetal reprogramming of a PPAR delta agonist
|
CN103269592B
(en)
|
2010-10-29 |
2016-05-11 |
默沙东公司 |
Cyclammonium replaces oxazolidone CETP inhibitor
|
MX351305B
(en)
|
2011-01-20 |
2017-10-09 |
Merck Sharp & Dohme |
Mineralocorticoid receptor antagonists.
|
MY159058A
(en)
|
2011-02-25 |
2016-12-15 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
BR112014003704A2
(en)
|
2011-09-19 |
2017-03-07 |
Eth Zuerich |
ror gamma modulators
|
WO2013055606A1
(en)
|
2011-10-13 |
2013-04-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
JO3210B1
(en)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
Fused bicyclic oxazolidinone cetp inhibitor
|
CN104411710A
(en)
|
2012-04-16 |
2015-03-11 |
卡内克制药公司 |
Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
|
WO2013169648A1
(en)
|
2012-05-07 |
2013-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
|
KR20150022974A
(en)
|
2012-06-19 |
2015-03-04 |
인터셉트 파마슈티컬즈, 인크. |
Preparation, uses and solid forms of obeticholic acid
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
MX2015001500A
(en)
|
2012-08-02 |
2015-04-08 |
Merck Sharp & Dohme |
Antidiabetic tricyclic compounds.
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
CA2898482A1
(en)
|
2013-02-22 |
2014-08-28 |
Linda L. Brockunier |
Antidiabetic bicyclic compounds
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
EP2781217A1
(en)
|
2013-03-18 |
2014-09-24 |
ETH Zurich |
ROR gamma modulators
|
ES2811087T3
(en)
|
2013-09-09 |
2021-03-10 |
Vtv Therapeutics Llc |
Use of PPAR-delta agonists to treat muscle atrophy
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CN106456998B
(en)
|
2014-04-17 |
2020-07-28 |
默沙东公司 |
Sitagliptin tannate complex
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
WO2017011279A1
(en)
|
2015-07-13 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
CN105732561A
(en)
*
|
2016-03-10 |
2016-07-06 |
中国药科大学 |
Homoisoflavonoids aromatic acid, aromatic acid ester derivative, method for preparing homoisoflavonoids aromatic acid and aromatic acid ester derivative and medicinal application thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
WO2020074958A1
(en)
|
2018-10-12 |
2020-04-16 |
Strongbridge Dublin Limited |
Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
WO2020236688A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
EP3972589A4
(en)
|
2019-05-22 |
2023-04-26 |
Merck Sharp & Dohme LLC |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
IL300610A
(en)
|
2020-08-18 |
2023-04-01 |
Merck Sharp ַ& Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
WO2023147309A1
(en)
|
2022-01-25 |
2023-08-03 |
Reneo Pharmaceuticals, Inc. |
Use of ppar-delta agonists in the treatment of disease
|